TuisANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Vorige sluiting
$0,00020
Markkapitalisasie
5,24 k USD
Gemiddelde volume
11,64 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
OTCMKTS
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | 2017info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 7,94 m | -28,30% |
Netto inkomste | -26,87 m | 51,60% |
Netto winsgrens | — | — |
Wins per aandeel | -3,80 | 70,53% |
EBITDA | -36,15 m | 36,48% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | 2017info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,20 m | -89,46% |
Totale bates | 3,67 m | -84,35% |
Totale aanspreeklikheid | 9,17 m | -13,70% |
Totale ekwiteit | -5,50 m | — |
Uitstaande aandele | 23,40 m | — |
Prys om te bespreek | -0,00 | — |
Opbrengs op bates | -167,77% | — |
Opbrengs op kapitaal | -619,42% | — |
Kontantvloei
Netto kontantverandering
| (USD) | 2017info | J/J-verandering |
|---|---|---|
Netto inkomste | -26,87 m | 51,60% |
Kontant van bedrywe | -36,90 m | 24,57% |
Kontant van beleggings | — | — |
Kontant van finansiering | 18,25 m | -22,58% |
Netto kontantverandering | -18,65 m | 28,58% |
Beskikbare kontantvloei | -23,15 m | 18,17% |
Meer oor
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Gestig
2004
Hoofkwartier
Webwerf
Werknemers
21
